[
  {
    "ts": null,
    "headline": "Regeneron (REGN) Draws Higher Target From TD Cowen",
    "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is included among the 13 Companies that Just Started Paying Dividends. During the Q4 2025 earnings call, CEO Leonard Schleifer said Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) delivered steady revenue growth. Fourth-quarter sales rose 3% from a year earlier. He said the increase came from double-digit growth across three key products. Global net [因",
    "url": "https://finnhub.io/api/news?id=356ef6aa64f51d04423666295799492154101fd1dd2dd63b64f98fe81ced9289",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769895433,
      "headline": "Regeneron (REGN) Draws Higher Target From TD Cowen",
      "id": 138319165,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is included among the 13 Companies that Just Started Paying Dividends. During the Q4 2025 earnings call, CEO Leonard Schleifer said Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) delivered steady revenue growth. Fourth-quarter sales rose 3% from a year earlier. He said the increase came from double-digit growth across three key products. Global net [因",
      "url": "https://finnhub.io/api/news?id=356ef6aa64f51d04423666295799492154101fd1dd2dd63b64f98fe81ced9289"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals, Inc. (REGN) Posts Q4 Earnings Beat, EPS Shines",
    "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the most profitable healthcare stocks to buy. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) reported Q4 2025 results on January 30, with revenue coming in at $3.9 billion (+3.0% year over year), which were around 3% ahead of consensus. Profitability was even better with adjusted EPS for the quarter reaching $11.44, 7% [因",
    "url": "https://finnhub.io/api/news?id=a9aad2aaa8c5fb9397c087a3936039379c58ad8f53c2aae50342189584a0a1c7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769880954,
      "headline": "Regeneron Pharmaceuticals, Inc. (REGN) Posts Q4 Earnings Beat, EPS Shines",
      "id": 138316696,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the most profitable healthcare stocks to buy. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) reported Q4 2025 results on January 30, with revenue coming in at $3.9 billion (+3.0% year over year), which were around 3% ahead of consensus. Profitability was even better with adjusted EPS for the quarter reaching $11.44, 7% [因",
      "url": "https://finnhub.io/api/news?id=a9aad2aaa8c5fb9397c087a3936039379c58ad8f53c2aae50342189584a0a1c7"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron: Expect Double-Digit Growth In 2026",
    "summary": "Regeneron Pharmaceuticals, Inc. targets double-digit 2026 growth via Dupixent expansion and fewer Eylea headwinds. Check out why REGN stock is a buy.",
    "url": "https://finnhub.io/api/news?id=a768dabc4b0ba12d5dbcd4119c847ff7618f45a825e5450369e2dbe4c76373b0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769848427,
      "headline": "Regeneron: Expect Double-Digit Growth In 2026",
      "id": 138314970,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1481194928/image_1481194928.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Regeneron Pharmaceuticals, Inc. targets double-digit 2026 growth via Dupixent expansion and fewer Eylea headwinds. Check out why REGN stock is a buy.",
      "url": "https://finnhub.io/api/news?id=a768dabc4b0ba12d5dbcd4119c847ff7618f45a825e5450369e2dbe4c76373b0"
    }
  }
]